We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to Deliver Lead Molecules
News

GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to Deliver Lead Molecules

GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to Deliver Lead Molecules
News

GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to Deliver Lead Molecules

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GVK Biosciences and Crelux set up Fragment-based Drug Discovery Platform to Deliver Lead Molecules"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GVK Biosciences and CRELUX announced that they have set-up a fragment-based drug discovery platform to deliver viable lead molecules.

CRELUX’s high performance structural biology technologies together with GVK BIO’s mature computer-assisted drug design (CADD) tools and other components of its drug discovery & development engine, encompass all steps from challenging targets to novel drug candidates.

CRELUX and GVK BIO will provide integration of all aspects of structure-based drug design for the Biopharmaceutical industry and furnishes accelerated timelines for moving molecules from concept into the clinic at an optimal cost.

Fragment-based Drug Design (FBDD) helps in visualizing binding modes and hence rationalize an accelerated SAR allowing efficient lead optimization through CADD. CRELUX will leverage its capabilities of all aspects of multifaceted structural studies towards X-ray elucidation of fragment or lead target complexes, whereas GVK BIO will perform all discovery chemistry and biology work including in silico, in vitro and in vivo studies as well as activities necessary to ensure pre-clinical candidate nomination.

“Collaborating with a renowned life-sciences service provider like GVK BIO in a fast emerging and competitive area like fragment-based drug discovery is a strong appreciation of our high quality services. Together we have generated a truly one-stop-shop from target-to-IND and support our customers with comprehensive drug discovery services”, commented Dr. Michael Schäffer, Executive Director, Business of CRELUX.

“GVK BIO is committed to further advance the discovery tools and services that are needed to systematically profit from the enhanced understanding of biochemical pathways and important molecular target families", said Sven Wagner, Ph.D., Vice President, Discovery Business Development for GVK BIO.

"With a strong alliance partner like CRELUX, GVK BIO is moving in the direction of its vision of being a global leader in life-sciences services” said Manni Kantipudi, President, GVK BIO.
Advertisement